Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Enanta Pharmaceuticals Stock Forecast NASDAQ:ENTA
Price Target and Analyst Ratings
Most Recent Rating
On Nov 24, 2021 "Oppenheimer" gave "$55.00 - $73.00" rating for ENTA. The price target was set to $86.76+0.3%.
Last 30 Days
Historical Ratings
| Date | Rating | Action | Authority | Current Price | Target Price |
|---|---|---|---|---|---|
| 2021-11-24 | $55.00 - $73.00 | Target Raised by | Oppenheimer | $86.89 | $86.76+0.3% |
| 2021-11-23 | $111.00 - $116.00 | Target Raised by | JMP Securities | $86.50 | $83.63+11.2% |
| 2021-11-23 | $107.00 - $101.00 | Target Lowered by | Roth Capital | $86.50 | $84.74+12.7% |
| 2021-11-23 | $92.00 - $85.00 | Target Lowered by | SVB Leerink | $86.50 | $80.47+7.0% |
| 2021-11-23 | $111.00 - $116.00 | Reiterated by | JMP Securities | $86.50 | $80.47+7.0% |
| 2021-11-08 | $71.00 - $130.00 | Target Raised by | Robert W. Baird | $94.24 | $97.69+0.3% |
| 2021-11-08 | $77.00 - $121.00 | Target Raised by | JMP Securities | $94.24 | $97.69+0.3% |
| 2021-11-08 | $55.00 - $92.00 | Target Raised by | SVB Leerink | $94.24 | $97.69+0.3% |
| 2021-10-20 | $58.00 - $74.00 | Target Raised by | Royal Bank of Canada | $72.00 | $71.07+1.8% |
| 2021-10-20 | $73.00 - $77.00 | Target Raised by | JMP Securities | $72.00 | $71.07+1.8% |
| 2021-10-20 | $73.00 - $78.00 | Reiterated by | JMP Securities | $72.00 | $71.60+2.6% |
| 2021-10-06 | Initiated by | Jefferies Financial Group | $61.20 | $61.20+1.1% | |
| 2021-09-09 | $55.00 | Initiated by | SVB Leerink | $55.82 | $57.17+0.1% |
| 2021-08-06 | $70.00 - $77.00 | Target Raised by | JMP Securities | $44.85 | $46.25+8.9% |
| 2021-08-06 | $52.00 - $50.00 | Target Lowered by | Royal Bank of Canada | $44.85 | $46.17→0.2% |
| 2021-02-09 | In-Line - Sector Perform | Target Raised by | Royal Bank of Canada | $54.73 | $47.00 → $53.00 |
| 2021-01-29 | Underweight - Neutral | Upgraded by | JPMorgan Chase & Co. | $48.06 | $55.00 |
| 2021-01-29 | Underweight - Neutral | Upgraded by | JPMorgan Chase & Co. | $48.06 | $44.00 → $55.00 |
| 2020-11-24 | Sector Perform | Target Lowered by | Royal Bank of Canada | $42.89 | $52.00 → $45.00 |
| 2020-11-23 | Underperform | Initiated by | Evercore ISI | $43.67 | |
| 2020-10-26 | Buy | Target Raised by | Roth Capital | $43.50 | $104.00 → $107.00 |
| 2020-09-23 | Hold | Reiterated by | Oppenheimer | $43.36 | $55.00 |
| 2020-08-27 | Buy | Initiated by | Roth Capital | $49.67 | |
| 2020-08-25 | Overweight | Initiated by | Piper Sandler | $50.64 | |
| 2020-08-06 | Hold | Reiterated by | Royal Bank of Canada | $46.31 | |
| 2020-08-04 | Hold | Initiated by | Oppenheimer | $47.69 | $55.00 |
| 2020-07-27 | Market Perform - Outperform | Upgraded by | JMP Securities | $50.32 | $70.00 |
| 2020-05-07 | Hold | Reiterated by | Oppenheimer | $50.68 | $62.00 |
| 2020-04-08 | Hold | Reiterated by | Royal Bank of Canada | $52.17 | $49.00 |
ENTA Stock Trend
Given the current short-term trend, the stock is expected to rise 53.17% during the next 3 months and, with a 90% probability hold a price between $114.59 and $169.71 at the end of this 3-month period.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2021-12-10 | $75.42 | $93.42 | $111.41 |
| 2021-12-13 | $76.03 | $94.03 | $112.02 |
| 2021-12-14 | $76.64 | $94.64 | $112.63 |
| 2021-12-15 | $77.25 | $95.25 | $113.24 |
| 2021-12-16 | $77.86 | $95.86 | $113.85 |
| 2021-12-17 | $78.47 | $96.47 | $114.46 |
| 2021-12-20 | $79.08 | $97.08 | $115.08 |
| 2021-12-21 | $79.69 | $97.69 | $115.69 |
| 2021-12-22 | $80.30 | $98.30 | $116.30 |
| 2021-12-23 | $80.92 | $98.91 | $116.91 |
| 2021-12-27 | $81.53 | $99.52 | $117.52 |
| 2021-12-28 | $82.14 | $100.13 | $118.13 |
| 2021-12-29 | $82.75 | $100.74 | $118.74 |
| 2021-12-30 | $83.36 | $101.35 | $119.35 |
| 2021-12-31 | $83.97 | $101.96 | $119.96 |
| 2022-01-03 | $84.58 | $102.57 | $120.57 |
| 2022-01-04 | $85.19 | $103.18 | $121.18 |
| 2022-01-05 | $85.80 | $103.80 | $121.79 |
| 2022-01-06 | $86.41 | $104.41 | $122.40 |
| 2022-01-07 | $87.02 | $105.02 | $123.01 |
| 2022-01-10 | $87.63 | $105.63 | $123.62 |
| 2022-01-11 | $88.24 | $106.24 | $124.23 |
| 2022-01-12 | $88.85 | $106.85 | $124.84 |
| 2022-01-13 | $89.46 | $107.46 | $125.45 |
| 2022-01-14 | $90.07 | $108.07 | $126.06 |
| 2022-01-17 | $90.68 | $108.68 | $126.67 |
| 2022-01-18 | $91.29 | $109.29 | $127.29 |
| 2022-01-19 | $91.90 | $109.90 | $127.90 |
| 2022-01-20 | $92.52 | $110.51 | $128.51 |
| 2022-01-21 | $93.13 | $111.12 | $129.12 |
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The companys research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease i... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 100 000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
